Company: WHWK
Filing Date: 2025-01-21
Form Type: PREM14A
Source: 0001193125-25-009599
Chunk: 258

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-21
Form: PREM14A
Chunk 258
---
 and certain closing conditions. Upon the closing of this transaction, Kaken will also acquire the rights to the Aadi name and 
 trademark.                                                                                                                                                                                                                                      |

License Agreement. On December 19, 2024, we entered into an Intellectual Property License Agreement (the “License Agreement”) with WuXi Biologics (Shanghai FX) Co., Ltd. (“WuXi Biologics”) for exclusive rights to certain patents and know-how pertainingto WuXi Biologics’ pre-clinical antibodydrug conjugate programs leveraging Hangzhou DAC Biotechnology Co., Ltd.’s (“Hangzhou DAC”) linker-payload technology targeting each of Mucin-16 (“MUC16”),Protein Tyrosine Kinase 7 (“PTK7”) and Seizure Related 6 Homolog (“SEZ6”) (each an “ADC Program,” and collectively, the “ADC Programs”). Under the License Agreement, we agreed to pay WuXi Biologics a non-refundable, partialupfront payment of $6 million and an additional non-refundable, upfrontpayment of $38 million within ninety (90) days after the effective date of the License Agreement, which may be extended by either party for an additional thirty (30) days, in each case, for the rights and licenses granted to us by WuXi Biologics. In accordance with the License Agreement, WuXi Biologics is eligible to receive from us (a) up to an aggregate of $265 million upon the achievement of certain development milestones, and (b) up to an aggregate of $540 million upon the achievement of certain commercial milestones, in each case, across all ACD Programs. WuXi Biologics is also entitled to running royalties during the agreed upon royalty term ranging from low-single-digit toupper-single-digit percentages of annual net sales of licensed products in the territory.

| • |     | PIPE Financing. On December 19, 2024, Aadi entered into the Subscription Agreement with PIPE                                                                                                                                                                                                                                                                                 
 Investors, pursuant to which Aadi agreed to sell to the PIPE Investors (i) 21,592,000 shares of Aadi’s common stock, par value $0.0001 per share, at a purchase price of $2.40 per share, and (ii) 20,076,500 Pre-Funded Warrants, at a purchase price of $2.3999 per Pre-Funded Warrant, for aggregate gross proceeds of $100 million. The closing of the PIPE Financing is